Join Us in Exploring Innovative Treatments for Plaque Psoriasis

This study evaluates the efficacy and safety of Ixekizumab alone or in combination with Tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight. It is a Phase 3b, randomized, multicenter, open-label study (TOGETHER-PsO).

New York location for dermatology study by Equity Medical
Study Location
New York
Office Address

200 Amsterdam Ave. New York, NY 10023

Office Phone
646-413-6020

Overview

Recruiting start date
  • 11/01/24
Duration
  • 36 Weeks
Study Drug

Ixekizumab / Tirzepatide

Delivery

Subcutaneous Injection

Sponsor

Eli Lilly and Company

Phase

3

Mechanism of Action

Non-radiographic axial spondyloarthritis, targets and neutralize the interleukin-17A (IL-17A) protein.

Inclusion Criteria
  • Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.
  • Have both a Static Physician’s Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) ≥12.
  • Have ≥10% body surface area (BSA) involvement.
  • Have a body mass index (BMI) of ≥27 kilograms per meter squared (kg/m²).
Exclusion Criteria
  • Have Type 1 Diabetes Mellitus (T1DM).
  • Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
  • Have a prior or planned surgical treatment for obesity.
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
  • Have active, or a history of inflammatory bowel disease (Crohn’s or ulcerative colitis).
  • Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions: basal cell or squamous epithelial carcinomas of the skin or cervical carcinoma in situ.
  • Have serious disorder or illness other than PsO.
  • Have a history of chronic or acute pancreatitis.
  • Have any prior use of Ixekizumab or Tirzepatide.
  • Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.
Important Notes:

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive Ixekizumab and Tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving Ixekizumab.

Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open-label treatment period, and post-treatment follow-up period.

Studies
Contact us to join a dermatology study clinical trial

Contact Us Today!

Whether it be eczema, dandruff, or psoriasis, being a part of our research is an impactful way to explore treatments and medications. Even if there isn’t a current study that’s a perfect fit for you, take the first step and sign up to learn more and be considered for future studies in New York and Kentucky. Click the button below to get started!